Overview

• Isomorphic Labs is poised to begin first-in-human trials for oncology-focused candidates generated by its AlphaFold-powered AI design platform.
• The company was spun out of Google DeepMind in 2021 following AlphaFold’s breakthrough in high-precision protein structure prediction.
• Major research collaborations with Novartis and Eli Lilly in 2024 and a $600 million funding round led by Thrive Capital in April 2025 have underwritten its clinical push.
• By modeling protein–ligand interactions with advanced machine learning, Isomorphic aims to shorten traditional drug development timelines and reduce costs while boosting success probabilities.
• Initiating human testing represents a pivotal step toward realizing the company’s vision of a world-class AI-driven drug design engine.